NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

learningcurve2020,

Pseudoprogressors did, information arm did, at least some to most original compassionate use did when not enough tumor was removed to make 5 doses. What is interesting is that the rGBM trial is using only 3 doses to achieve immune memory ie long term survival. So what does that tell you about the actual amount of tumor needed and therefore the number of patients that will be eligible for treatment when this becomes SOC?; ). Getting treatment earlier, eliminating treatment from SOC that actually interferes with benefit in some patients, adding Poly ICLC by clinician choice or SOC, adding checkpoint inhibitors for those identifiable as beneficiaries, adding CSF-R1 to those identified as beneficiaries and potentially 1 or 2 other treatments to help those that still need it after this and I believe the cure rate will be very close to 100% because of immune memory being established. I also think that a toned down or modified Direct can be used in some situations with the patient being monitored for a while to achieve the same thing for inoperable patients. The way this all unfolds once given a chance will be amazing to watch. Best wishes.